Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of the stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $16.15, for a total value of $161,500.00. Following the completion of the transaction, the insider now directly owns 723,510 shares of the company’s stock, valued at $11,684,686.50. The sale was disclosed in a filing with the SEC, which is available at this link.
Sharon Shacham also recently made the following trade(s):
- On Wednesday, February 7th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $125,000.00.
- On Monday, January 8th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.08, for a total value of $100,800.00.
Shares of Karyopharm Therapeutics Inc (KPTI) opened at $16.86 on Friday. Karyopharm Therapeutics Inc has a twelve month low of $7.48 and a twelve month high of $16.93.
A number of equities analysts have recently issued reports on the company. BidaskClub raised Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. Royal Bank of Canada reissued a “buy” rating and issued a $22.00 target price on shares of Karyopharm Therapeutics in a report on Friday, March 2nd. HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Karyopharm Therapeutics in a report on Tuesday, December 12th. ValuEngine raised Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, January 25th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $18.11.
TRADEMARK VIOLATION NOTICE: “Karyopharm Therapeutics Inc (KPTI) Insider Sharon Shacham Sells 10,000 Shares” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/03/11/karyopharm-therapeutics-inc-kpti-insider-sharon-shacham-sells-10000-shares.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.